0090-9556/04/3205-545-551$20.00
DMD 32:545-551, 2004
AMIDE N-GLUCURONIDATION OF MAXIPOST CATALYZED BY UDP-GLUCURONOSYLTRANSFERASE 2B7 IN HUMANS
Donglu Zhang,
Weiping Zhao,
Vikram A. Roongta,
James G. Mitroka,
Lewis J. Klunk, and
Mingshe Zhu
Pharmaceutical Candidate Optimization, Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey
MaxiPost [(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indole-2-one), or BMS-204352)] is a potent and specific maxi-K channel opener for potential use to treat stroke. This article describes structural characterization of a major human N-glucuronide metabolite of BMS-204352 and identification of the enzyme responsible for the N-glucuronidation reaction. After intravenous administrations of [14C]BMS-204352 (10 mg, 50 µCi) to eight healthy human subjects, one major metabolite M representing an average of 17% of the radioactive dose was excreted in pooled urine collected over 0 to 336 h after dosing. A major biliary metabolite of dogs dosed with [14C]BMS-204352 (5 mg/kg), which represented about 33% of the dose, has the same retention time and the same tandem mass spectrometry fragmentation pattern as the human urinary metabolite M. Four hundred fifty micrograms of the metabolite was isolated from the dog bile and analyzed by NMR. Long-range 1H-13C NMR experimentation indicated that the glucuronic acid moiety was at the nitrogen site. The N-glucuronide of BMS-204352 was stable up to 24 h at 37°C in the incubations at different pH values (3.0, 7.4, and 9.0) and with glucuronidases from Escherichia coli and Helix pomatia. Of the seven human UDP-glucuronosyltransferases (UGT) isozymes (1A1, 1A3, 1A4, 1A6, 1A7, 1A10, and 2B7) tested, only UGT2B7 produced metabolite M. UGT2B7-catalyzed N-glucuronidation of BMS-204352 exhibited Michaelis-Menten kinetics with a Km of 14.2 µM and Vmax of 0.29 nmol/min · mg of protein. Collectively, these results suggest that amide N-glucuronidation, a major elimination pathway of MaxiPost, is catalyzed by UGT2B7 in humans. This N-glucuronide represents a fully characterized amide N-glucuronide, and glucuronidation at the nitrogen represents a newly identified conjugation reaction for UGT2B7.
Address correspondence to: Dr. Donglu Zhang, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research Institute, Route 206 and Province-Line Road, Princeton, NJ 08543. E-mail: donglu.zhang{at}bms.com
This article has been cited by other articles:

|
 |

|
 |
 
B. Zhu, D. Bush, G. A. Doss, S. Vincent, R. B. Franklin, and S. Xu
Characterization of 1'-Hydroxymidazolam Glucuronidation in Human Liver Microsomes
Drug Metab. Dispos.,
February 1, 2008;
36(2):
331 - 338.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kaivosaari, P. Toivonen, L. M. Hesse, M. Koskinen, M. H. Court, and M. Finel
Nicotine Glucuronidation and the Human UDP-Glucuronosyltransferase UGT2B10
Mol. Pharmacol.,
September 1, 2007;
72(3):
761 - 768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Xu, D. M. Krenitsky, A. M. Seacat, J. L. Butenhoff, T. R. Tephly, and M. W. Anders
N-GLUCURONIDATION OF PERFLUOROOCTANESULFONAMIDE BY HUMAN, RAT, DOG, AND MONKEY LIVER MICROSOMES AND BY EXPRESSED RAT AND HUMAN UDP-GLUCURONOSYLTRANSFERASES
Drug Metab. Dispos.,
August 1, 2006;
34(8):
1406 - 1410.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Rowland, D. J. Elliot, J. A. Williams, P. I. Mackenzie, R. G. Dickinson, and J. O. Miners
IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION
Drug Metab. Dispos.,
June 1, 2006;
34(6):
1055 - 1062.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Zhang, R. Krishna, L. Wang, J. Zeng, J. Mitroka, R. Dai, N. Narasimhan, R. A. Reeves, N. R. Srinivas, and L. J. Klunk
METABOLISM, PHARMACOKINETICS, AND PROTEIN COVALENT BINDING OF RADIOLABELED MAXIPOST (BMS-204352) IN HUMANS
Drug Metab. Dispos.,
January 1, 2005;
33(1):
83 - 93.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. G. Staines, M. W. H. Coughtrie, and B. Burchell
N-Glucuronidation of Carbamazepine in Human Tissues Is Mediated by UGT2B7
J. Pharmacol. Exp. Ther.,
December 1, 2004;
311(3):
1131 - 1137.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.